- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04646005
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
October 2, 2023 updated by: Regeneron Pharmaceuticals
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
The secondary objectives of the study are:
- To characterize the safety profile of cemiplimab + ISA101b
- To assess preliminary efficacy of cemiplimab + ISA101b as measured by duration of response (DOR), progression-free survival (PFS), and overall survival (OS)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
113
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium, 1160
- CHIREC Delta Hospital / Chirec Cancer Institute
-
-
East Flanders
-
Gent, East Flanders, Belgium, 9000
- Universitair Ziekenhuis Gent
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- UZ Leuven
-
-
-
-
-
Rio de Janeiro, Brazil, 22793-080
- Instituto COI de Pesquisa, Educacao e Gestao - COI Clinicas Barra Da Tijuca (COI Clinicas Oncologicas Integradas SA)
-
-
Rio De Janeiro
-
Santo Cristo, Rio De Janeiro, Brazil, 20220-410
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva ¿ INCA
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
- Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
-
-
Santa Catarina
-
Itajai, Santa Catarina, Brazil, 88301-220
- Centro De Novos Tratamentos Itajai
-
-
Sao Paulo
-
Barretos, Sao Paulo, Brazil, 14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
-
-
-
-
Milan, Italy, 20141
- IRCCS-Istituto Europeo di Oncologia
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italy, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 08308
- Korea University Guro Hospital
-
Seoul, Korea, Republic of, 06273
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of, 05505
- University of Ulsan College of Medicine - Asan Medical Center (AMC)
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
Leiden, Netherlands, 2333 ZA
- Leiden Universitair Medisch Centrum (LUMC)
-
Nijmegen, Netherlands, 6525 GA
- Radboudumc
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 HX
- Maastricht University Medical Center
-
-
-
-
Krasnodar Region
-
Krasnodar, Krasnodar Region, Russian Federation, 350040
- State Budgetary Healthcare Institution Clinical Oncology Dispensary 1 Of Healthcare Department Of Krasnodar Region
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
-
Catalonia
-
Girona, Catalonia, Spain, 17007
- Hospital Doctor Josep Trueta - Institut Catala d'Oncologia (ICO)
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Arizona Oncology Associates
-
Tucson, Arizona, United States, 85711
- Arizona Oncology Associates
-
-
California
-
Orange, California, United States, 92868
- Regeneron Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Adult patients ≥18 years of age (or the legal age of adults to consent to participate in a clinical study per country specific regulations).
- Has histologically confirmed recurrent or metastatic HPV16 positive cervical cancer as determined by an investigational HPV16 PCR assay, who have experienced disease progression after treatment with platinum containing therapy as defined in the protocol
- Patient must be determined to be positive for HPV16 genotype, as determined by a specified central reference laboratory.
- Patient must have measurable disease as defined by RECIST 1.1.
- Must have received prior bevacizumab and taxol unless meets pre-specified protocol criteria
- ECOG performance status of 0 or 1.
- Has adequate organ and bone marrow function as defined in the protocol.
- Anticipated life expectancy ≥20 weeks.
Key Exclusion Criteria:
- Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
- Prior treatment with other systemic immune-modulating agents as defined in the protocol
- Major surgery or radiation therapy within 14 days of first administration of study drug
- Has received treatment with an approved systemic therapy within 4 weeks of first dose of study drug, or has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities except for laboratory changes as described in the protocol
- Has another malignancy that is progressing or requires active treatment and/or history of malignancy other than cervical cancer within 3 years of date of first planned dose of study drug as defined in the protocol
- Has any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 4 weeks prior to the first dose of study drug. 7. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
NOTE: Other protocol-defined Inclusion/ Exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cemiplimab+ISA101b
|
Administered intravenously (IV) every three weeks (Q3W)
Other Names:
Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate (ORR)
Time Frame: Until disease progression, up to 36 months
|
Until disease progression, up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of treatment emergent adverse events (TEAEs)
Time Frame: Up to 90 days after the last dose of study treatment
|
Up to 90 days after the last dose of study treatment
|
Incidence and severity of adverse events of special interest (AESIs)
Time Frame: Up to 90 days after the last dose of study treatment
|
Up to 90 days after the last dose of study treatment
|
Incidence and severity of serious adverse events (SAEs)
Time Frame: Up to 90 days after the last dose of study treatment
|
Up to 90 days after the last dose of study treatment
|
Incidence and severity of ≥ grade 3 laboratory abnormalities
Time Frame: Up to 90 days after the last dose of study treatment
|
Up to 90 days after the last dose of study treatment
|
Duration of response (DOR)
Time Frame: Until disease progression, up to 36 months
|
Until disease progression, up to 36 months
|
Progression free survival (PFS)
Time Frame: Until disease progression, up to 36 months
|
Until disease progression, up to 36 months
|
Overall survival (OS)
Time Frame: Up to 60 months
|
Up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Actual)
May 22, 2023
Study Completion (Estimated)
October 22, 2024
Study Registration Dates
First Submitted
November 20, 2020
First Submitted That Met QC Criteria
November 20, 2020
First Posted (Actual)
November 27, 2020
Study Record Updates
Last Update Posted (Actual)
October 3, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Disease Attributes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Disease Progression
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Cemiplimab
Other Study ID Numbers
- R2810-ONC-ISA-1981
- 2020-001239-29 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli.
Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Cemiplimab
-
Ottawa Hospital Research InstituteOntario Institute for Cancer ResearchNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingRecurrent Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma | Stage I Skin Cancer | Stage II Skin Cancer | Stage III Skin CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteRegeneron PharmaceuticalsTerminatedCutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell CarcinomaUnited States
-
Regeneron PharmaceuticalsPacific Pediatric Neuro-Oncology ConsortiumTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System TumorUnited States
-
Regeneron PharmaceuticalsSanofiNo longer availableCutaneous Squamous Cell Carcinoma
-
Reinhard DummerSanofi; Sun Pharmaceutical Industries LtdRecruiting
-
University of MiamiRegeneron PharmaceuticalsWithdrawnHead and Neck Squamous Cell Carcinoma | HNSCC | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of Hypopharynx
-
Regeneron PharmaceuticalsCompletedAdvanced Cutaneous Squamous Cell CarcinomaUnited States, Spain, France, Italy, Australia, Germany, Brazil, Greece
-
Regeneron PharmaceuticalsActive, not recruitingBasal Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States, Puerto Rico